Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9UKF6
UPID:
CPSF3_HUMAN
Alternative names:
Cleavage and polyadenylation specificity factor 73 kDa subunit; mRNA 3'-end-processing endonuclease CPSF-73
Alternative UPACC:
Q9UKF6; O14769; Q53RS2; Q96F36
Background:
Cleavage and polyadenylation specificity factor subunit 3, also known as CPSF-73, plays a pivotal role in mRNA 3'-end formation, recognizing the AAUAAA signal sequence. It exhibits endonuclease activity, crucial for pre-mRNA processing and histone 3'-end pre-mRNA processing. CPSF-73's involvement in cell cycle progression and microRNA biogenesis underscores its multifunctionality in cellular processes.
Therapeutic significance:
The protein's link to Neurodevelopmental disorder with microcephaly, hypotonia, nystagmus, and seizures highlights its clinical relevance. Understanding CPSF-73's role could open doors to potential therapeutic strategies for this genetic disorder.